FREMONT, Calif.--(BUSINESS WIRE)--2006 Corporate Progress and Outlook “Several important accomplishments were made in 2006,” said Dan Denney, Jr., Ph.D., Genitope Corporation’s Chairman and Chief Executive Officer. “We initiated a clinical trial for MyVax® personalized immunotherapy for the treatment of chronic lymphocytic leukemia, we made important advancements with our monoclonal antibody program, and several key hires were made that strengthened our organization. Additionally, in February of 2007, we released updated information on our pivotal phase 3 clinical trial using MyVax® personalized immunotherapy. We are encouraged by the update as it demonstrated a positive trend toward progression free survival based on the observed slowing of the rate of cancer progressions in the patients in the still blinded study. Results from the 287 patient trial are expected by year end.”
